Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01470937 · ClinicalTrials.gov registry record · Phase 4

Early Diabetes Intervention Program

A Phase 4 study, sponsored by Indiana University.

Completed
Registry status
Phase 4
Development phase
219
Enrollment target

NCT01470937: Completed Phase 4 study, sponsored by Indiana University.

NCT01470937 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 219 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01470937, a Phase 4 study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 4
Development phase
219 participants
Enrollment target

Study Summary

This is an evaluation of the effect of acarbose to delay worsening of fasting glucose control in early Type 2 diabetes mellitus.

Primary Outcome

Fasting plasma glucose was measured quarterly for up to 5 years. Two consecutive measures above 140 mg/dL defined progression.

Interventions

  • DRUG Placebo
  • DRUG Acarbose

Trial Details

FieldValue
Enrollment Target 219 participants
Start Date 1998-02
Est. Completion 2004-09
Phase Phase 4
Indiana University

890 total trials

What the finished NCT01470937 record still lists

NCT01470937 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01470937 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01470937 about?

NCT01470937 is a clinical study titled "Early Diabetes Intervention Program". This is an evaluation of the effect of acarbose to delay worsening of fasting glucose control in early Type 2 diabetes mellitus.

What is the current status of trial NCT01470937?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 219 participants. The study started on 1998-02. Estimated completion is 2004-09.

What interventions are being tested in trial NCT01470937?

The interventions under investigation include: Placebo (DRUG), Acarbose (DRUG).

Who is sponsoring clinical trial NCT01470937?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01470937's enrollment target sits among peer trials

219 389th of 2000 higher than 1,611 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05196035 · 219 participants · Phase 3

    A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  • NCT05608434 · 219 participants · Phase 1

    Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

  • NCT05773144 · 219 participants · NA

    Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

  • NCT05907980 · 219 participants · Phase 1

    A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01470937, the US trial registry maintained by the National Library of Medicine. NCT01470937 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.